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Therapy in Practice: Assessment and Management of 
Neuropsychiatric Symptoms in Parkinson’s Disease 
 
 
Abstract (195/250) 
 
Neuropsychiatric symptoms are highly prevalent in Parkinson’s disease and associated with 
decreased quality of life and adverse health outcomes. In this review the assessment and 
management of common neuropsychiatric symptoms are discussed: depression, anxiety, 
psychosis, cognitive impairment, dementia and apathy. Validated assessment scales are now 
available for the majority of symptoms. Balancing dopaminergic therapy plays an important 
role in their management as increasing doses of dopaminergic agents might address depression 
and anxiety related to ‘off’ phases, nonmotor fluctuations and apathy, while dose reduction 
might alleviate psychotic symptoms. More targeted treatment is possible through medications 
utilizing different pathways. Although efficacy profiles of individual agents require further 
exploration, antidepressants as a drug class have shown utility in depression and anxiety in 
Parkinson’s disease. Psychological therapies, especially cognitive behavioral approaches, are 
effective. pimavanserin allows treatment of psychosis in Parkinson’s disease without directly 
affecting the dopaminergic and cholinergic system. The cholinergic system is currently the 
only target in in Parkinson’s disease dementia, and antagonists of this system, as are many 
psychotropics, need to be used with caution. Management of apathy largely relies on non-
pharmacological strategies adapted from dementia care, with antidepressants being ineffective 
and the role of stimulant therapy needing further evaluation.  
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Key points: 3-4 sentences 
 
• Neuropsychiatric are closely interwoven with motor symptoms and nonmotor 
fluctuations, making differentiation challenging, and leading to underdiagnoses and 
underreporting.  
 
• The increasing availability of validated, easy-to-use, screening tools might allow 
earlier recognition in clinical practice. 
 
• Adjustment of dopaminergic therapy plays an important role and dopaminergic 
agonists with the potential to simultaneously address motor and non-motor symptoms 
such as depression or apathy have shown promising potential. 
 
• There is acceptable evidence for acetylcholinesterase inhibitors (dementia), clozapine 
(hallucinations), and antidepressants. 
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1. Introduction 
 
Neuropsychiatric symptoms are common already at the time of diagnosis of Parkinson’s 
disease (PD) [1] and in more advanced stages their impact is often greater than that of motor 
symptoms. The most frequent symptoms are depression, hallucinations and apathy and many 
patients have more than one symptom, adding to the complexity and challenge both for patients 
and for their caregivers [2]. Neuropsychiatric symptoms are strong predictors of poor quality 
of life and key drivers for nursing home admission and thus are costly for society. This review 
gives an overview on clinical presentation, diagnostic tools and management strategies for 
neuropsychiatric symptoms in PD. The electronic database PubMed Medline was searched 
with the search terms “Parkinson OR Parkinson’s disease OR PD“ and ”neuropsychiatric OR 
depression OR anxiety OR fatigue OR apathy OR cognition OR cognitive decline OR dementia 
OR psychosis OR hallucination OR apathy OR fatigue“. Cross-references from the identified 
articles were also scrutinised for relevant studies. Articles were selected through authors 
consensus with a focus on studies evaluating treatment interventions as well as recent state-of-
the-art review articles. Assessment instruments for individual symptoms are described in the 
relevant subsections below, but an initial screening can be conducted using scales covering 
multiple symptoms. Instruments covering several symptoms include the Neuropsychiatric 
Inventory (NPI) [3], or the Non-Motor Symptoms Scale for Parkinson's disease (NMSS) [4]. 
Of note, the revised Movement Disorder Society (MDS) version of the Unified Parkinson 
Disease Rating Scale (UPDRS) has an increased focus on neuropsychiatric symptoms [5], 
demonstrating the increased acknowledgement of the relevance of these symptoms as part of 
the core syndrome.   
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2. Depression  
 
Depression in PD is associated with increased caregiver burden and mortality, as well as 
decreased functioning, quality of life and possibly cognitive decline [6, 7]. Although the 
prevalence rates vary considerably according to sample definitions and assessment criteria, 
about one third [8] of patients with PD are considered to suffer from clinically relevant 
depressive symptoms. A family history of depression and previous depressive episodes, as well 
as female gender, early onset of PD and other neuropsychiatric symptoms have been identified 
as possible risk factors for depression in PD [9]. Neurobiological factors that might play a role 
are degeneration in the serotonergic raphe nucleus and noradrenergic locus coeruleus as well 
as dysregulation of the dopaminergic circuits in the frontostriatal and mesolimbic regions [10]. 
 
 
2.1 Assessment  
 
Low mood, reduced energy and capacity for enjoyment (anhedonia) are the core symptoms of 
depression. Other features include disturbed sleep, changes in appetite and weight, impaired 
concentration, slowness of thinking and movement and a blunted affect. However, many of 
these can overlap with symptoms of PD, in particular in the advanced stages, making the 
distinction between the two difficult [11].  
 
Clinically it can be helpful to consider fatigability of movement in PD in contrast to general 
slowness in depression, impaired concentration in depression compared to a more generalized 
cognitive impairment pointing towards dementia in PD and the longitudinal course of sleep 
disturbances, whereby a more recent onset might indicate depression [12]. Negative 
cognitions, such as guilt or worthlessness are less common in depression in Parkinson’s 
disease [13]. In clinical settings diagnosis of depression should be made according to the 
International Classification of Disease version ten (ICD-10) [14] or Diagnostic and Statistical 
Manual of Mental Disorders, Fifth Edition (DSM-5) [15] criteria, and screening tools can be 
useful. Although suicidality is less common in patients with PD than in the general 
population this should always be assessed.  
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An additional challenge specific to PD is the differentiating depression from non-motor 
fluctuations, fatigue, apathy (see Chapter 6) or dementia (see Chapter 5).  
Non-motor fluctuations are related to wearing-off of dopaminergic therapy and can present as 
low mood, anxiety, apathy or fatigue. They are might present in the absence of motor 
fluctuations and often difficult to diagnose in clinical practice [16]. Several assessment tools 
have been developed (such as the Non-Motor Fluctuation Assessment [17] or the 19-item 
Wearing-OFF Questionnaire as screening tool [18]) for research settings. In routine clinical 
settings it is crucial to establish whether neuropsychiatric symptoms improve after the patient 
has administered a dopaminergic agonist. 
 
Fatigue is a diagnostic criterion for depression or anxiety [15], but can also be a primary feature 
of PD [19]. Evidence on successful treatment strategies of primary fatigue in Parkinson’s 
disease is missing [20] and the use of antidepressants cannot be recommend in the treatment 
of fatigue, unless a diagnosis of depression according to established criteria is present. 
Although it is important to identify fatigue as part of a depressive syndrome, a considerable 
number of patients will complain about unresolved fatigue after successful treatment of 
depressive symptoms [21]. 
 
The last potential diagnostic pitfall is distinguishing dementia in PD from depression, as the 
cognitive profile of late-life depression, with characteristic difficulties in attentional and 
executive domains, is very similar to dementia in PD [22, 23]. Pointers towards a diagnosis of 
depression rather than dementia might be a subacute onset of symptoms over days to weeks 
rather than months, a mismatch between functional impairment and cognitive test scores, 
greater awareness of cognitive deficits, saying ‘I don’t know’ rather than confabulating 
answers in testing, as well as preserved visuospatial abilities [23-25]. In uncertain cases, use of 
in-depth neuropsychological testing or use of biomarkers on cognitive decline (see Chapter 5) 
should be considered.  
 
A recent meta-analysis [26] identified three tools to be specific and sensitive for detecting 
depression in PD: the 15-item Geriatric Depression Scale (GDS-15), Beck Depression 
Inventory (BDI-I or Ia); Montgomery-Åsberg Depression Rating Scale (MADRS). Not enough 
data is available to conduct a meta-analyse of psychometric properties related to detecting 
depression for instruments such as the Hamilton Depression Rating Scale (HAM-D), the 
Hospital Anxiety and Depression Scale (HADS) and the Zung Self-Rating Depression Scale 
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(SDS). These were they were included in a critique by a taskforce of the Movement Disorders 
Society, which also provides adjusted cut-off scores compared to those in non-PD populations  
[27].  
 
The GDS-15 [28] is an ideal screening tool as it is available in the public domain, translated 
into several languages and quick to administer. The GDS-15 is a self-rated tool which takes 5-
10 minutes to administer, asking yes/no questions. Its focus on cognitive and social aspects of 
depression, rather than somatic concerns, and reduces the impact of motor symptoms on the 
overall score. A cut-off of 5 appears to be appropriate as this yields a sensitivity of 91% [26]. 
 
The BDI [29], HAM-D [30]  (Hamilton, 1960) and MADRS [31] can be used both as screening 
tools, but also to measure change over time.  
The BDI is self-rated and takes 5-10 minutes to administer and the HAM-D and MADRS are 
clinician rated and take 10-15 and 15-20 minutes to administer. The HAM-D is the most 
frequently administered tool in clinical trials to measure efficacy and has been classified as 
most suitable for assessing depression severity in research settings [27].  
 
If time-pressures in clinical practice do not allow the regular use of structured tools, focus 
should be on detecting depression using a short screening tool as GDS-15. In general hospital 
settings and primary care, the UK National Institute for Health and Care Excellence (NICE) 
[32] recommends the use of a two-question screen to detect depression, asking two ‘yes/no’ 
questions: ‘During the last month, have you often been bothered by feeling down, depressed 
or hopeless?’ and ‘During the last month, have you often been bothered by having little interest 
or pleasure in doing things?’. A recent meta-analysis found that this tool had a sensitivity of 
92% and a specificity of 68% in older adults and its performance is comparable with other 
instruments in this population [33].  Although this needs formal validation in PD, it might be 
a useful and cost-effective approach to screen for depression in this population.  
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2.2 Management 
 
A holistic approach is essential in the management of depression in PD. Assessment tools and 
a treatment algorithm are illustrated in Figure 1. Organic causes (e.g. hypothyroidism) need to 
be excluded and if present addressed. 
 
It is important to determine if depressive symptoms are only seen in ‘off’ periods or are due to 
non-motor fluctuations. In these circumstances adjustment of dopaminergic or other 
medications prescribed for motor symptoms can alleviate symptoms, and is more likely to be 
beneficial than depression-specific treatments [34].  Established strategies for the treatment of 
motor symptoms can be followed, but care should be taken in older patients, those with 
orthostatic hypotension and co-morbid other neuropsychiatric symptoms [11]. Adding 
pramipexole, a dopaminergic agonist with probable antidepressant properties [35], could be 
considered.  
 
In milder cases guided self-help, psychoeducation, advice on exercise and sleep hygiene, 
support groups and/or involvement of the support network are often sufficient. Cognitive 
behaviour therapy (CBT) is the best evaluated non-pharmacological intervention [36, 37], 
showing good effects on depressive and secondary anxiety symptoms in PD, both administered 
individually or in group settings. Pachana and colleagues [7] argue that CBT needs to address 
factors specifically relevant to patients with PD such as beliefs about their illness and the 
impact of disability. Working with grief and loss (of functioning) are important [38], especially 
as these can ameliorate anxiety over the future and enable better coping with disability.  A 
specific focus should be on regaining functioning that has been lost due to avoidance rather 
than inability. As PD is a neurodegenerative disease with progressive deterioration it is unclear 
if the benefits of psychological therapies are sustained after the intervention concludes.  A 
further limiting factor for CBT interventions are practical obstacles to attending therapy, such 
as living in remote areas, lack of transportation or caregiver support, or fluctuations in motor 
symptoms [39]. There has been a recent effort to develop telehealth interventions, which have 
indicated feasibility and good retention rates, but require larger scale evaluation [40-45]. 
 
In moderate to severe depression, or where non-pharmacological measures haven’t been 
successful, drug treatment should be considered. Antidepressant medication can further be 
 10 
helpful in reducing symptoms to a level that enable patients to engage with psychological 
therapy.  
 
Although their effect sizes are modest and not all clinical trials report superiority to placebo, 
due to their benign safety profile selective serotonin re-uptake inhibitors (SSRI) are considered 
first-line treatments [37]. Superiority to placebo in randomized clinical trials has been 
demonstrated for citalopram, paroxetine and the serotonin–norepinephrine reuptake inhibitor 
(SNRI) venlafaxine [46, 47]. Venlafaxine was not superior to paroxetine [47] and no advantage 
to placebo was reported in other trials for citalopram, paroxetine, as well as sertraline  [37]. It 
has however been speculated that placebo responses might be exaggerated in PD due to the 
release of dopamine in anticipation of a therapeutic benefit  [48, 49].  One needs to be aware 
of an increased risk of a serotonin syndrome when SSRIs and the MAO-B inhibitor selegeline 
are co-prescribed [50] and the SNRI venlafaxine has been associated with a worsening of motor 
symptoms [47].  
 
The tricyclic antidepressants (TCAs) nortriptyline and desipramine (the active metabolite of 
imipramine) appear to have larger effect sizes compared to placebo than SSRIs and a more 
rapid onset of benefits [46, 51]. This is probably related to their effect on the adrenergic and 
dopaminergic system, as well as improvement of sleep [37]. These agents could be of benefit 
when a more rapid resolution of depressive symptoms is desired (e.g. low food or fluid intake, 
suicidal ideation, psychotic depression). The flipside of this is that TCAs are associated with 
adverse effects on the cardiovascular system and the propensity to worsen autonomic 
dysfunction, and should be used with caution in those with cardiovascular disorders, orthostatic 
hypotension, urinary retention and angle closure glaucoma [11]. Anticholinergic effects could 
improve motor symptoms, but they are likely to worsen psychotic symptoms and cognition 
(see Chapter 4). Practical considerations are that SSRIs/SNRIs should be given in the mornings 
and TCAs at night. While SSRIs are usually started at the therapeutic dose, SNRIs and TCAs 
require titration [11]. We recommend starting with an SSRI and considering venlafaxine or 
TCA if insufficient effect or side-effects occur. Antidepressant dosing should follow 
recommended schedules for treatment of major depressive disorder in the elderly (for example 
[52]).  
 
The potential antidepressant role of dopamine agonists, in particular pramipexole, has been of 
interest due to the possibility of addressing both motor and non-motor symptoms with a single 
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agent. Larger scale observational studies [53, 54] have shown beneficial effects of pramipexole 
specifically on anhedonia in PD depression, and a small head-to-head trial equivalent efficacy 
to sertraline [55]. One large double-blind placebo controlled RCT in patients with mild to 
moderate depression [35] showed small, but statistically significant, benefits of pramipexole 
compared to placebo. Groups who might benefit from pramipexole as first line treatment for 
PD depression are those who were recently diagnosed patients with PD suffering from mood 
symptoms, but have not been started on dopaminergic therapy; when symptoms occurred after 
a reduction in dopaminergic therapy; or when non-motor fluctuations could be the main driver 
of depressive symptoms  [56, 57]. 
In other clinical contexts, treating motor and depressive symptoms with separate agents, and 
only using dopaminergic agents as second line treatments, might allow a more personalised 
approach [56]. 
Adverse effects of dopaminergic agents also need to be considered as well as the increased risk 
of psychosis (see Chapter 4) and impulse control disorders [58]. Pramipexole should be started 
on a low dose and titrated up over weeks, as an acute challenge can lead to worsening of mood 
and motivation [59]. 
 
 
Repetitive transcranial magnetic stimulation (rTMS) for depression led to improvement of 
symptoms, but these were not statistically significant compared to placebo treatment in two 
small studies [60, 61]. A more recent study of multifocal rTMS didn’t show improvements of 
depressive symptoms and inferiority to sham treatment [62]. For life-threatening and treatment-
resistant depression in Parkinson’s disease electro-convulsive therapy (ECT) should be 
considered. No randomized controlled trials have been conducted using ECT in depression in 
PD, but case series and case reports have described benefits on depressive, psychotic (Chapter 
4) as well as motor symptoms. A limiting factor is that the risk of delirium or transient 
confusion appears to substantial in this patient group, being reported in more than a third of 
patients treated [63]. 
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3. Anxiety 
 
Anxiety disorders are more common in patients with PD than in the general population or those 
with other chronic conditions  [64], with about one third suffering from a diagnosable anxiety 
disorder [65].  
Most common are generalised anxiety disorder (GAD), with the typical symptoms of persistent 
tension, irrational worrying and physical arousal; phobias, especially social phobias, and panic 
disorders [66].  
 
3.1 Assessment 
 
Compared to general populations, PD patients with anxiety more frequently suffer from 
internal tremor, as well as social or anticipatory anxiety [7, 65]. Common scales to assess 
anxiety, such as the Hospital Anxiety and Depression Scales (HADS), Hamilton Anxiety 
Rating Scale (HARS) and Beck Anxiety Inventory (BAI) are not appropriate to be used in PD 
[67]. Dissanayaka and colleagues [68]  reviewed the literature on anxiety rating scales in PD 
and found that two scales have good validity and reliability: The Geriatric Anxiety Inventory 
(GAI) and the Parkinson’s Anxiety scale (PAS). 
 
The GAI is a 20-item self-report measure [69], using ‘agree/disagree’ responses, which takes 
about 10 minutes to administer. It focuses on cognitive symptoms of anxiety and less on 
somatic symptoms making it appropriate for use in PD [70]; a cut-off of 7 suggests an anxiety 
disorder. The PAS is a newly developed scale [71] and is a 12-item self- or observer-rated tool. 
Items are scored on a 5-point Likert scale, whereby 0 = ‘not or never’ and 4 = ‘severe or almost 
always’. The optimal cut-off point to detect anxiety is 14. The self-rated version takes 2 minutes 
to complete and the observer rating 5 minutes. Sensitivity to change in anxiety in PD has not 
yet been evaluated.   
 
 
3.2 Management 
 
As in depression, a comprehensive assessment is needed to rule out other potential causes for 
anxiety (e.g. metabolic causes) or substance use. In particular, it should be established if 
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anxiety is present in an ‘off’ phase or due to nonmotor fluctuations and can be ameliorated by 
adjusting dopaminergic medication.  
 
 CBT is a well-established treatment for anxiety disorders and likely to be efficacious in PD 
[7]. The majority of studies have shown reduction of anxiety in the context of depression in 
PD, but a recent small study focussing primarily on anxiety demonstrated benefits in a small 
study of 12 patients [66]. For milder cases self-help should be encouraged.  
 
No controlled studies have been conducted for antidepressants in anxiety in PD, but secondary 
benefits are reported from antidepressant studies [9]. Case studies have suggested benefits for 
citalopram, sertraline and paroxetine [72], but no beneficial effects for secondary anxiety in 
depression were shown in a randomized controlled trial for paroxetine and venlafaxine [47]. 
For disabling cases or where the anxiety causes the patient severe distress short-term treatment 
with benzodiazepines can be initiated for up to four weeks. In addition to their potential to 
cause physical dependence, benzodiazepines affect cognition, alertness and gait in patients 
with PD increasing the risk of falls [73]. 
  
 14 
4. Psychosis 
 
PD psychosis is a term used to describe the range of illusions, hallucinations and delusions 
occurring in PD and related disorders (see Table 1 for typical manifestations in PD) [for review 
see 74]. In early PD the symptoms are predominantly illusions (a real object misperceived as 
something else) including pareidolia, a specific subtype of illusion. Other early symptoms 
include passage hallucinations and presence hallucinations. A range of other visual 
disturbances including isolated diplopia and spatial misjudgement have also been recently 
described [75, 76]. These early symptoms are sometimes referred to collectively as minor 
hallucinations. As PD progresses, formed visual hallucinations occur, typically of people or 
animals [often insects or small animals, 77]. At this stage insight into the fact they are 
hallucinations is preserved or, if absent when the experiences first occur, patients can learn to 
recognise that the experiences are hallucinations. In later stages, insight becomes impaired so 
that the experiences may no longer be recognised as hallucinations. Other hallucination 
modalities may also occur, either as separate hallucinations or as multimodality hallucinations 
that may be seen and heard at the same time. These experiences may occur alongside false 
beliefs (delusions) that can be linked to the hallucinations (secondary delusions) or have 
unrelated themes such as infidelity or persecution. Themes involving identity are referred to 
collectively as misidentification delusions. The typical progression of PD psychosis is 
illustrated in Figure 2.  The boundary between different stages is blurred, and mirrors that of 
cognitive decline with early symptoms occurring without detectible cognitive change, formed 
hallucinations occurring at the mild cognitive impairment (PD-MCI) stage and hallucinations 
without insight and misidentification delusions in the context of dementia in PD (PDD). The 
prevalence of PD psychosis increases with disease duration, with most patients eventually 
developing such symptoms. However, estimates vary depending on whether minor symptoms 
are included. In cross-sectional studies, typical rates of complex visual hallucinations range 
from 22%-38% and auditory hallucinations around half this value (0%-22%) [78]. Patients who 
present with PD psychosis early in the disease have accelerated cognitive decline and worse 
longer-term outcomes [74]. In particular, visual hallucinations are associated with the move 
from living independently into a care setting, irrespective of motor impairment or cognitive 
ability [79].  
 
The underlying cause of PD psychosis is currently unclear. Early theories linked PD psychosis 
to the use of dopamine therapy and it remains the case that PD psychosis often starts after the 
 15 
onset of dopamine therapy and may improve with dose reduction. However, evidence that PD 
psychosis can occur without the use of dopamine medication and a lack of relationship between 
medication dose and symptom severity shows the relationship is complex. Current consensus 
on the role of dopamine therapy [see 80] is that PD psychosis may be integral to PD itself but 
triggered or modified by the use of dopamine medication. A reduction in striatal dopamine 
binding in PD prior to the onset of PD-Psychosis supports this view [81]. Other suggested 
pathophysiological mechanisms for PD psychosis include alterations in serotonergic function 
[82] and, based on evidence from DLB, alterations in cholinergic function [83]. There is also 
evidence for a specific profile of cognitive deficits in PD psychosis, including deficits in 
memory, executive function, visuo-spatial function and attention [for review see 74]. The 
cognitive changes are consistent with the distribution of cortical and hippocampal atrophy [for 
review see 74, 84]. PD psychosis is associated Lewy body, Tau and amyloid pathology [85] 
although whether the distribution or such pathology matches the distribution of cortical atrophy 
is unclear [74].           
 
4.2 Assessment 
Assessment of PD psychosis is carried out by clinical examination of the mental state, with 
information from a carer required in later stages of the disease. The stigma of visual 
hallucinations as a sign of mental illness may mean patients are reluctant to admit the symptoms 
in early stages so that direct and sensitive questioning is required. A range of quantitative 
assessment tools are used in research settings (Scale for the Assessment of Positive Symptoms 
– Parkinson’s disease-adopted (SAPS-PD), North-East Visual Hallucinations Interview 
(NEVHI) and Neuropsychiatric Inventory (NPI)) but none cover the whole range of symptoms 
encountered in PD psychosis. There are no specific investigations for PD psychosis but where 
symptoms are atypical, further investigation may be required. For example, in a patient with 
visual hallucinations restricted to a portion of the visual field, detailed visual field testing, MRI 
of visual pathways and visual electrophysiology may be indicated.   
 
4.3 Management 
The management of PD psychosis differs across the disease course with the different treatment 
considerations for each stage illustrated in Figure 2. A key consideration throughout is the 
influence of dopamine therapy and the competing priorities of increasing dopamine therapy to 
optimise motor function and decreasing dopamine therapy to reduce PD psychosis symptoms. 
Other factors that require constant review are anti-muscarinic medication load [for example 
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using traffic-light coding of medication, 86], general physical health to rule out infection and 
delirium and optimisation of vision, for example through referral to ophthalmology. In early 
stages of disease, management by re-assurance, education and self-help strategies to stop 
hallucinations (for example, changes in lighting, eye movements or general alerting strategies) 
may be sufficient. For formed hallucinations that cause distress, psychological interventions to 
reduce general stress or designed specifically for visual hallucinations [87] may be helpful 
while insight is still present but as distress increases or insight is lost, medication may become 
the only option. Cholinesterase inhibitors, e.g. Rivastigmine may have a particularly good 
cognitive effect in people with hallucination in PD  [88] but patients may already be on this 
medication for cognitive decline.  Pimavanserin (a 5HT2A inverse agonist) has been recently 
approved for the treatment of PD psychosis and can be considered if available [89]. Clozapine 
is effective for PD psychosis but blood monitoring requirements may limit its practicality for 
some patients [90, 91]. Quetiapine is widely used because of its favourable extrapyramidal 
side-effect profile and has recommended in the 2017 [92]. However, clinical trial evidence to 
support a specific treatment role in PD psychosis is limited with several trials showing no effect 
over placebo [93-95]. Where treatment using these medications is ineffective or impractical, 
there is open label trial evidence to support the use of ECT [96, 97] or continuous subcutaneous 
apomorphine as an alternative to oral dopamine therapy [98] for PD psychosis [74].    
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Table 1 PD psychosis symptom phenomenology 
 
SYMPTOM  TYPICAL MANIFESTATION IN PD 
MINOR  Illusion Brief misperception of one object for another.     
 Pareidolia  Faces or animals triggered by visual context, for example by 
wallpaper / carpet patterns, tree bark or clouds. Pareidolia is a 
normal perceptual experience that increases in frequency in PD and 
DLB.  
 Passage 
hallucination 
A figure or person is seen moving past in the peripheral visual field 
and disappears on looking towards it.    
 Presence 
hallucination 
Sense of someone being next to you without seeing or hearing the 
person.  
COMPLEX 
HALLUCINATION 
 Typically seeing a person or animal when not present. The person 
may be someone known. The experience may be recognised as a 
hallucination (insight present) or believed to be real (insight absent).   
Insight may also fluctuate or be partial such that the hallucination is 
recognised as having been false after the event but acted on as if real 
at the time it occurred.  
PSEUDO-
HALLUCINATION 
 Term used in the neurological literature to describe hallucinations 
with insight present. In psychiatric literature the term is used to 
describe vivid imagery (seen in mind’s eye not external visual 
environment).     
DELUSION  False belief typically of guilt, persecution or jealousy. If linked to a 
hallucination referred to as a secondary delusion (e.g. beliefs about 
the identify and intent of a hallucinated figure).  
MISIDENTIFICATION 
DELUSION 
 Specific categories of false belief linked to identity. Capgras 
delusion is the belief that a relative has been replaced by an 
impostor. Reduplicative paramnesia is the belief that a specific 
location has been duplicated.   
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5. Cognitive decline and dementia 
 
Cognitive decline is one of the most common non-motor symptoms in PD and people with PD 
have substantially increased risk of developing dementia compared to the general population. 
The point prevalence of dementia in people with PD is about 25-30% and the majority of 
patients with PD develop dementia if they survive 10 years or more from initial diagnosis [22]. 
Risk factors for a more rapid cognitive decline include more severe parkinsonism, especially 
bradykinesia and rigidity, higher age [99], the presence of visual hallucinations [100] and 
reduced Aβ42 levels in the cerebrospinal fluid [101]. Importantly, among PD patients without 
dementia 25-30% suffer from mild cognitive impairment [22]. 
 
Parkinson’s disease dementia (PDD) and mild cognitive impairment in PD (PD-MCI) are 
operationalised as two separate entities, whereby the hallmark for PDD is that cognitive 
problems are sufficiently severe to impair activities of daily living independently of co-existing 
motor or autonomic symptoms [102, 103]. Up to one fifth [99] of patients present with PD-
MCI at the stage of PD diagnosis, which is associated with a more rapid progression to 
dementia. However, a considerable proportion of these patients also revert back to normal 
cognition after one year [104].  
 
The main pathological correlate of dementia in autopsy studies is the presence of cortical and 
limbic Lewy bodies (α-synucleinopathies) [105]. Other proteinopathies, with the evidence for 
amyloid plaques being more robust than for tau-pathology, contribute to the development of 
dementia and seem to have an additive influence [106, 107]. Both dopaminergic and non-
dopaminergic transmitter deficits underlie cognitive decline and the cholinergic system appears 
to be affected early in the disease course of PD [108]. 
 
 
5.1 Assessment 
 
Timely diagnosis of cognitive impairment and dementia in PD is important and operationalised 
diagnostic criteria exist [102, 103]. For a diagnosis of  PDD [102] required core features are a 
diagnosis of PD and cognitive impairment in more than one domain, which is severe enough 
to impair activities of daily living. To make a diagnosis of probable, as opposed to possible, 
PDD a typical cognitive profile with impairment in at least two of the following domains needs 
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to be present: (I) attention (may fluctuate during the day or from day to day), (II) executive 
function, (III) visuo-spatial function and (IV) memory, in particular free recall, which usually 
improves with cueing.  
Due to clinical and pathological overlap, the distinction of dementia in PD and dementia with 
DLB is challenging and the temporal sequence of symptoms is used to guide differential 
diagnosis. PDD develops in the context of established PD, and if dementia develops before or 
within one year of motor features of parkinsonism, DLB should be diagnosed. Although useful 
for research settings, the 1-year-rule is often difficult to apply in clinical practice since the 
exact timing of motor and cognitive symptoms may be difficult to establish [102]. However, 
this distinction is mainly of academic relevance, the clinical management is the same in PDD 
and DLB.  
 
Although comprehensive neuropsychological testing is the gold standard, cognitive rating 
scales are useful in clinical practice for screening and monitoring. A Movement Disorder 
Society review committee recently made recommendations regarding the use of these tools 
[109]. The Montreal Cognitive Assessment battery (MoCA) [110], Mattis Dementia Rating 
Scale Second Edition (DRS-2) [111] (MD-11), and the Parkinson’s Disease-Cognitive Rating 
Scale (PD-CRS) [112] were endorsed. The most appropriate scale in clinical settings appears 
to be the MoCA as administration only takes around 10 minutes and it is sensitive to change 
over time [113]. Suggested cut-off points are for <26 PD-MCI and <21 for PDD [114]. Scales 
traditionally used in dementia services as the Mini-Mental State Examination (MMSE) [115] 
and Adenbrooks’s Cognitive Examination (ACE-R) [116] were not recommended. The MMSE 
primarily tests cortical aspects of cognition, which are frequently preserved in PD, to the 
expense of inadequate testing of visuospatial and executive dysfunction [109]. The ACE-R 
[116] has good psychometric properties, but limited coverage of executive dysfunction [109]. 
Further, the new ACE-III [117] which has been introduced due to copyright issues, has not 
been evaluated in PD populations. Other non-motor symptoms which are common in PDD 
should also be recorded and global scales such as NPI [3] or NMSS [4] can be applied. All 
scales can be used as guidance, but need to be accompanied by clinical assessment of degree 
of functional cognitive decline, focusing on work-related functioning and for home-dwelling 
patients tasks such as managing medication regime, finances, computer and mobile phones. 
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CT or structural MRI have limited usefulness in terms of distinguishing PDD from other forms 
of dementia. Patients with PDD show greater atrophy of frontal, parietal, occipital and temporal 
cortices [22] and the severity of dementia correlates with medial temporal lobe atrophy [118]. 
PET imaging of glucose metabolism or Amyloid-β might allow clearer distinction of PDD 
from Alzheimer’s disease, whereby amyloid-positive PET scans and reduced Aβ42 levels in 
the cerebrospinal fluid are also associated with more rapid cognitive decline in PD [22, 119].    
 
 
5.2 Management 
 
No disease-modifying treatments affecting cognition in PD are available and no 
pharmacological intervention has been demonstrated to affect the transition from PD-MCI to 
PDD. Whether caffeine and green tea, which appear to reduce the risk of developing PD, have 
a role in cognitive decline needs further exploration [120, 121].  
In PDD, cholinesterase inhibitors are established treatments, with evidence supporting the use 
of rivastigmine [122] and donepezil [123]. Positive, though modest, effects are reported on 
cognition, but also on activities of daily living and behavioural disturbances. Rivastigmine is 
the only cholinesterase inhibitor approved for the treatment of PDD in most countries and 
thereby widely used. There are yet no convincing differences to donepezil in efficacy, and 
choice of medication should largely rely on clinical considerations and patient preference. For 
example, ease of titration, the once daily administration and the possibly more benign side 
effect profile favours donepezil [124], while the opportunity of a gradual titration or application 
as a transdermal patch might make Rivastigmine the preferred choice.  
 
The partial N-methyl-D-aspartate receptor (NMDA)-antagonist memantine has a benign side 
effect profile, but only small positive global effects in one study [125]. As in PD psychosis, 
review and discontinuation of medications with central anticholinergic activity is likely to 
have positive effects on cognition, although a recent study indicated that medications with 
anticholinergic activity were not associated with more rapid cognitive decline in PD [126-
128].  
 
Non-pharmacological measures to improve cognition and potentially prevent or delay 
cognitive decline include physical exercise and cognitive training. An addition to improving 
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motor symptoms, exercise has been shown to improve cognition, mood and sleep. Aerobic or 
resistance exercise can improve cognition in PD, with evidence to suggest a positive effect of 
aerobic exercise on executive function [129]. Cognitive training improves executive 
functioning, working memory and processing speed in cognitively normal or mildly impaired 
patients with PD [130]. To which extent this benefit translates to cognition in general and is 
sustained beyond the duration of training needs further testing. 
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6. Apathy 
 
Apathy, loss or diminished motivation, is a multidimensional syndrome that includes reduced 
emotions, goal-directed behaviours, and cognitive activity [131]. The proposed diagnostic 
criteria for apathy has been validated in people with PD [132]. Up to one third of people with 
PD without depression or dementia have apathy, which is associated with high levels of 
disability, accelerated cognitive and functional decline, weight loss, poor quality of life [133], 
high caregivers’ burden, poor quality of care, poor rehabilitation, and increased risk of 
mortality [134-138]. Further, apathy may impair the ability to engage with treatment and care 
of other motor, cognitive, and behavioural symptoms. Structural and functional neuroimaging 
studies investigating apathy in PD have reported changes in right frontal lobe, orbitofrontal 
cortex, fusiform gyrus, insula, postcentral gyrus, inferior frontal gyrus, left middle frontal 
gyrus, bilateral cingulate gyrus, bilateral inferior parietal gyrus, and right precuneus [138].   
 
6.1 Assessment 
Apathy in PD has to be differentiated from depression, fatigue, psychosis, hypoactive delirium, 
and adverse effects of medications as this is essential for planning appropriate treatment and 
avoiding unnecessary medication. A good clinical and collateral history, mental status 
examination, physical examination, use of assessment instruments, and direct behavioural 
observation help to clarify differential diagnoses. Apathy presents with diminished 
spontaneous emotions and emotional responsiveness. Self-reported low mood, depressive 
cognitions, guilt ideas, negative self-appraisal, and diurnal variation are common in depression 
but not in apathy. Besides, peripheral and central fatigue are common in PD, and more than 
77% of people with PD have clinically significant fatigue[139]. Despite the clinical overlap, 
apathy can be reliably distinguished from fatigue by the absence of physical aspects of 
fatigue[140]. Moreover, acute onset and temporal correlation with medication changes indicate 
the possibility of adverse drug effects. A hypoactive delirium is characterised by attentional 
deficits, fluctuating cognition, physical examination, and relevant laboratory examinations. 
Apathy may present alone or in association with other neuropsychiatric symptoms. The G 
domain of the NPI [3], and the UDPRS’s item on apathy [5] can be used to screen for the 
presence of apathy. Specific instruments, such as the apathy scale [141], the apathy evaluation 
scale [142], and the Lille Apathy Rating Scale [143], are available for assessment and 
monitoring the progress of apathy in PD [144].  
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6.2 Management 
 
Because of limited pharmacological options, non-pharmacological interventions should be 
tried first, and be continued in combination with pharmacological interventions for managing 
apathy in PD. These have largely been evaluated in the context of dementia and preliminary 
evidence support the potential of tailored therapeutic mentally stimulating activities, 
behavioural activation therapy, psychomotor therapy [145], physical exercise [146], social 
interaction [147], cognitive communication therapy [148], individualised functional 
enhancement programme [149], emotion-oriented care [150], cognitive stimulation therapy, 
live interactive music [151], and multisensory stimulation for improving apathy. 
Evidence supporting the efficacy of available pharmacological options for managing apathy in 
PD is not robust [152, 153]. Preliminary evidence indicate that L-dopa [154], dopaminergic 
agonists such as pramipexole [155] and ropinirole [156], and the glutamatergic antagonist 
amantadine [157] may improve apathy. However, clinical use of these medications has to be 
balanced with their adverse effects and their effects on other symptoms of PD. 
Psychostimulants have been tried to treat apathy in PD [158]. A small RCT has reported that 
methylphenidate could significantly improve apathy in people with dementia, who had 
moderate to severe apathy at baseline [159]. Another RCT evaluating the efficacy of 
atomoxetine in PD did not find any significant change in the severity of apathy [160].  
 
Acetylcholinesterase inhibitors have level II evidence to support their efficacy for managing 
apathy in non-PD dementia [152, 161]. Rivastigmine has been reported to improve the apathy 
in PD [162], but a recent longitudinal study did not confirm a prolonged effect after one year 
follow-up [163]. Antidepressants that are effective for the management of depression in PD 
have not been found helpful in the management of apathy in PD, for example the use of SSRIs 
has been associated with greater apathy in a retrospective chart review [157, 164, 165]. 
Prevailing evidence does not support the use of antipsychotic medications for treating apathy 
in PD, but stopping long-term antipsychotic medication may lead to worsening of apathy [166]. 
In the absence of robust evidence, optimising the dosage of dopaminergic medication and 
adding an acetylcholinesterase inhibitor are the first-line pharmacological options available for 
the off-label clinical management of apathy in PD.  
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There is little evidence to support the use of repetitive transcranial magnetic stimulation 
(rTMS), deep brain stimulation (DBS), ECT, or of transcranial direct current stimulation for 
managing apathy in PD. There have been reports of worsening of apathy following subthalamic 
and pallidal DBS [167, 168].  Withdrawal from dopamine agonist drugs and post-operative 
mesolimbic dopamine denervation may lead to new-onset apathy in people with PD [169]. A 
case series has reported short-term statistically significant improvement of apathy following 
rTMS [170].  
 
7. Conclusions 
 
Neuropsychiatric symptoms represent an important aspect of the clinical spectrum of PD, and 
a particular clinical focus needs to be on consistent recognition [171]. Simple psychosocial 
strategies should nearly always be considered, either face-to-face or remotely.  Importantly, 
dopaminergic medications can improve or worsen neuropsychiatric symptoms, and thus 
reviewing the anti-parkinson regime is an important step before commencing psychotropic 
treatment. In addition, patients with PDD should be considered for cholinesterase treatment.  
If depressive symptoms do not respond psychosocial interventions, SSRI or SNRI should be 
considered. Clozapine is the only antipsychotic supported by convincing evidence, but the risk 
for agranulocytosis and associated administrative hurdles have led to low prescription rates. 
Pimavanserin is a potential new agent but currently not available in Europe. 
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Figures: 
 
Figure 1 Management flow-chart for depression in PD 
CBT = Cognitive behaviour therapy; ECT = Electro-convulsive therapy; GDS-15 = 15-item 
Geriatric Depression Scale; MADRS = Montgomery-Åsberg Depression Rating Scale; 
HAM-D  = Hamilton Depression Rating Scale; SNRI = Serotonin–norepinephrine reuptake 
inhibitor; SSRI = Selective Serotonin Re-uptake Inhibitors; TCA = Tricyclic antidepressants 
 
 
Figure 2 Management algorithm for PD psychosis  
The right of the figures shows treatment options and considerations at different stages of PD 
psychosis. The dotted line indicates ongoing review of medication, general health and vision 
at the point of medication onset. Brackets indicated medications / ECT where clinical trial 
evidence for efficacy in PD psychosis is limited. See text for further details.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 26 
References: 
 
1. Aarsland D, Bronnick K, Alves G, Tysnes OB, Pedersen KF, Ehrt U, et al. The spectrum 
of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol 
Neurosurg Psychiatry. 2009 Aug;80(8):928-30. 
2. Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E, et al. Range of 
neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg 
Psychiatry. 1999 Oct;67(4):492-6. 
3. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The 
Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. 
Neurology. 1994 Dec;44(12):2308-14. 
4. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, et al. The 
metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results 
from an international pilot study. Mov Disord. 2007 Oct 15;22(13):1901-11. 
5. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. 
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating 
Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 
Nov 15;23(15):2129-70. 
6. Marsh L, McDonald WM, Cummings J, Ravina B, Depression NNWGo, Parkinson's D. 
Provisional diagnostic criteria for depression in Parkinson's disease: report of an 
NINDS/NIMH Work Group. Mov Disord. 2006 Feb;21(2):148-58. 
7. Pachana NA, Egan SJ, Laidlaw K, Dissanayaka N, Byrne GJ, Brockman S, et al. Clinical 
issues in the treatment of anxiety and depression in older adults with Parkinson's disease. 
Mov Disord. 2013 Dec;28(14):1930-4. 
8. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of 
prevalence studies of depression in Parkinson's disease. Mov Disord. 2008 Jan 30;23(2):183-
9; quiz 313. 
9. Aarsland D, Kramberger MG. Neuropsychiatric Symptoms in Parkinson's Disease. J 
Parkinsons Dis. 2015;5(3):659-67. 
10. Ehgoetz Martens KA, Lewis SJ. Pathology of behavior in PD: What is known and what 
is not? J Neurol Sci. 2017 Mar 15;374:9-16. 
11. Timmer MHM, van Beek M, Bloem BR, Esselink RAJ. What a neurologist should know 
about depression in Parkinson's disease. Pract Neurol. 2017 Oct;17(5):359-68. 
12. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson's disease. 
Mov Disord. 2009 Nov 15;24(15):2175-86. 
13. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson's disease: a 
quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry. 1986 Apr;49(4):381-9. 
14. World Health Organisation. International Statistical Classifications of Diseases and 
Related Health Problems. 10th Revision Vol 2 Instruction Manual. Geneva: World Health 
Organisation; 2010. 
15. American Psychiatric Association. Diagnostic and statistical manual of mental 
disorders DSM-5. . 5th edn. ed. Washington, DC: American Psychiatric Association; 2013. 
16. Storch A, Schneider CB, Wolz M, Sturwald Y, Nebe A, Odin P, et al. Nonmotor 
fluctuations in Parkinson disease: severity and correlation with motor complications. 
Neurology. 2013 Feb 26;80(9):800-9. 
 27 
17. Kleiner-Fisman G, Martine R, Lang AE, Stern MB. Development of a non-motor 
fluctuation assessment instrument for Parkinson disease. Parkinsons Dis. 
2011;2011:292719. 
18. Stacy M, Hauser R. Development of a Patient Questionnaire to facilitate recognition 
of motor and non-motor wearing-off in Parkinson's disease. J Neural Transm (Vienna). 2007 
Feb;114(2):211-7. 
19. Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms 
of Parkinson's disease. Mov Disord. 2001 May;16(3):507-10. 
20. Elbers RG, Verhoef J, van Wegen EE, Berendse HW, Kwakkel G. Interventions for 
fatigue in Parkinson's disease. Cochrane Database Syst Rev. 2015 Oct 8(10):CD010925. 
21. Robinson RL, Stephenson JJ, Dennehy EB, Grabner M, Faries D, Palli SR, et al. The 
importance of unresolved fatigue in depression: costs and comorbidities. Psychosomatics. 
2015 May-Jun;56(3):274-85. 
22. Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, et al. 
Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017 Apr;13(4):217-31. 
23. Karantzoulis S, Galvin JE. Distinguishing Alzheimer's disease from other major forms 
of dementia. Expert Rev Neurother. 2011 Nov;11(11):1579-91. 
24. Vertesi A, Lever JA, Molloy DW, Sanderson B, Tuttle I, Pokoradi L, et al. Standardized 
Mini-Mental State Examination. Use and interpretation. Can Fam Physician. 2001 
Oct;47:2018-23. 
25. Wright SL, Persad C. Distinguishing between depression and dementia in older 
persons: neuropsychological and neuropathological correlates. J Geriatr Psychiatry Neurol. 
2007 Dec;20(4):189-98. 
26. Goodarzi Z, Mrklas KJ, Roberts DJ, Jette N, Pringsheim T, Holroyd-Leduc J. Detecting 
depression in Parkinson disease: A systematic review and meta-analysis. Neurology. 2016 Jul 
26;87(4):426-37. 
27. Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, et al. 
Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 
2007 Jun 15;22(8):1077-92. 
28. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and 
validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 
1982;17(1):37-49. 
29. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring 
depression. Archives of general psychiatry. 1961 Jun;4:561-71. 
30. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 
Feb;23:56-62. 
31. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to 
change. Br J Psychiatry. 1979 Apr;134:382-9. 
32. Pilling S, Anderson I, Goldberg D, Meader N, Taylor C, Two Guideline Development G. 
Depression in adults, including those with a chronic physical health problem: summary of 
NICE guidance. BMJ. 2009 Oct 27;339:b4108. 
33. Tsoi KK, Chan JY, Hirai HW, Wong SY. Comparison of diagnostic performance of Two-
Question Screen and 15 depression screening instruments for older adults: systematic 
review and meta-analysis. Br J Psychiatry. 2017 Apr;210(4):255-60. 
34. Classen J, Koschel J, Oehlwein C, Seppi K, Urban P, Winkler C, et al. Nonmotor 
fluctuations: phenotypes, pathophysiology, management, and open issues. J Neural Transm 
(Vienna). 2017 Aug;124(8):1029-36. 
 28 
35. Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole 
for the treatment of depressive symptoms in patients with Parkinson's disease: a 
randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010 Jun;9(6):573-80. 
36. Yang S, Sajatovic M, Walter BL. Psychosocial interventions for depression and anxiety 
in Parkinson's disease. J Geriatr Psychiatry Neurol. 2012 Jun;25(2):113-21. 
37. Bomasang-Layno E, Fadlon I, Murray AN, Himelhoch S. Antidepressive treatments for 
Parkinson's disease: A systematic review and meta-analysis. Parkinsonism Relat Disord. 
2015 Aug;21(8):833-42; discussion  
38. K. L, S. M. Cognitive behaviour therapy: how is it different with older people? . J 
Ration Emot Cogn Behav Ther. 2008;26:250-62. 
39. Dobkin RD, Menza M, Allen LA, Gara MA, Mark MH, Tiu J, et al. Cognitive-behavioral 
therapy for depression in Parkinson's disease: a randomized, controlled trial. Am J 
Psychiatry. 2011 Oct;168(10):1066-74. 
40. Veazey C, Cook KF, Stanley M, Lai EC, Kunik ME. Telephone-administered cognitive 
behavioral therapy: a case study of anxiety and depression in Parkinson's disease. J Clin 
Psychol Med Settings. 2009 Sep;16(3):243-53. 
41. Dobkin RD. The relationship between telephone-administered cognitive-behavioral 
therapy for depression and neuropsychological functioning in Parkinson's disease. The 
Journal of neuropsychiatry and clinical neurosciences. 2014 Apr 1;26(2):E10-1. 
42. Dobkin RD, Menza M, Allen LA, Tiu J, Friedman J, Bienfait KL, et al. Telephone-based 
cognitive-behavioral therapy for depression in Parkinson disease. J Geriatr Psychiatry 
Neurol. 2011 Dec;24(4):206-14. 
43. Lawson RA, Millar D, Brown RG, Burn DJ. Guided self-help for the management of 
worry in Parkinson's disease: a pilot study. J Parkinsons Dis. 2013;3(1):61-8. 
44. Kraepelien M, Svenningsson P, Lindefors N, Kaldo V. Internet-based cognitive 
behavioral therapy for depression and anxiety in Parkinson's disease — A pilot study. 
Internet Interventions. 2015 2015/03/01/;2(1):1-6. 
45. Calleo JS, Amspoker AB, Sarwar AI, Kunik ME, Jankovic J, Marsh L, et al. A Pilot Study 
of a Cognitive–Behavioral Treatment for Anxiety and Depression in Patients With Parkinson 
Disease. Journal of Geriatric Psychiatry and Neurology. 2015 2015/09/01;28(3):210-7. 
46. Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P, et al. Comparison of 
desipramine and citalopram treatments for depression in Parkinson's disease: a double-
blind, randomized, placebo-controlled study. Mov Disord. 2008 Apr 30;23(6):850-7. 
47. Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, et al. A 
randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. 
Neurology. 2012 Apr 17;78(16):1229-36. 
48. Lidstone SC, Schulzer M, Dinelle K, Mak E, Sossi V, Ruth TJ, et al. Effects of 
expectation on placebo-induced dopamine release in Parkinson disease. Archives of general 
psychiatry. 2010 Aug;67(8):857-65. 
49. de la Fuente-Fernandez R. The placebo-reward hypothesis: dopamine and the 
placebo effect. Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S72-4. 
50. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of 
depression in Parkinson's disease. Biological psychiatry. 2003 Aug 01;54(3):363-75. 
51. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, et al. A controlled trial 
of antidepressants in patients with Parkinson disease and depression. Neurology. 2009 Mar 
10;72(10):886-92. 
 29 
52. Joint Formulary Committee. British National Formulary. 69 ed. London: BMJ Group 
and Pharmaceutical Press; 2015. 
53. Reichmann H, Brecht MH, Koster J, Kraus PH, Lemke MR. Pramipexole in routine 
clinical practice: a prospective observational trial in Parkinson's disease. CNS Drugs. 
2003;17(13):965-73. 
54. Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H. Anhedonia, depression, 
and motor functioning in Parkinson's disease during treatment with pramipexole. The 
Journal of neuropsychiatry and clinical neurosciences. 2005 Spring;17(2):214-20. 
55. Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, et al. 
Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a 
national multicenter parallel-group randomized study. Journal of neurology. 2006 
May;253(5):601-7. 
56. Leentjens AF. The role of dopamine agonists in the treatment of depression in 
patients with Parkinson's disease: a systematic review. Drugs. 2011 Feb 12;71(3):273-86. 
57. Martinez-Fernandez R, Schmitt E, Martinez-Martin P, Krack P. The hidden sister of 
motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations. Mov Disord. 
2016 Aug;31(8):1080-94. 
58. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse 
control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 
2010 May;67(5):589-95. 
59. Drijgers RL, Verhey FR, Tissingh G, van Domburg PH, Aalten P, Leentjens AF. The role 
of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: a 
double blind randomized placebo-controlled experimental challenge with pramipexole and 
methylphenidate. J Neurol Sci. 2012 Sep 15;320(1-2):121-6. 
60. Fregni F, Santos CM, Myczkowski ML, Rigolino R, Gallucci-Neto J, Barbosa ER, et al. 
Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of 
depression in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004 
Aug;75(8):1171-4. 
61. Pal E, Nagy F, Aschermann Z, Balazs E, Kovacs N. The impact of left prefrontal 
repetitive transcranial magnetic stimulation on depression in Parkinson's disease: a 
randomized, double-blind, placebo-controlled study. Mov Disord. 2010 Oct 30;25(14):2311-
7. 
62. Brys M, Fox MD, Agarwal S, Biagioni M, Dacpano G, Kumar P, et al. Multifocal 
repetitive TMS for motor and mood symptoms of Parkinson disease: A randomized trial. 
Neurology. 2016 Nov 01;87(18):1907-15. 
63. Borisovskaya A, Bryson WC, Buchholz J, Samii A, Borson S. Electroconvulsive therapy 
for depression in Parkinson's disease: systematic review of evidence and recommendations. 
Neurodegener Dis Manag. 2016 Apr;6(2):161-76. 
64. Richard IH. Anxiety disorders in Parkinson's disease. Adv Neurol. 2005;96:42-55. 
65. Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE. 
Symptomatology and markers of anxiety disorders in Parkinson's disease: a cross-sectional 
study. Mov Disord. 2011 Feb 15;26(3):484-92. 
66. Dissanayaka NNW, Pye D, Mitchell LK, Byrne GJ, O'Sullivan JD, Marsh R, et al. 
Cognitive Behavior Therapy for Anxiety in Parkinson's Disease: Outcomes for Patients and 
Caregivers. Clin Gerontol. 2017 May-Jun;40(3):159-71. 
 30 
67. Forjaz MJ, Martinez-Martin P, Dujardin K, Marsh L, Richard IH, Starkstein SE, et al. 
Rasch analysis of anxiety scales in Parkinson's disease. J Psychosom Res. 2013 
May;74(5):414-9. 
68. Dissanayaka NN, Torbey E, Pachana NA. Anxiety rating scales in Parkinson's disease: 
a critical review updating recent literature. Int Psychogeriatr. 2015 Nov;27(11):1777-84. 
69. Pachana NA, Byrne GJ, Siddle H, Koloski N, Harley E, Arnold E. Development and 
validation of the Geriatric Anxiety Inventory. Int Psychogeriatr. 2007 Feb;19(1):103-14. 
70. Matheson SF, Byrne GJ, Dissanayaka NN, Pachana NA, Mellick GD, O'Sullivan JD, et 
al. Validity and reliability of the Geriatric Anxiety Inventory in Parkinson's disease. Australas 
J Ageing. 2012 Mar;31(1):13-6. 
71. Leentjens AF, Dujardin K, Pontone GM, Starkstein SE, Weintraub D, Martinez-Martin 
P. The Parkinson Anxiety Scale (PAS): development and validation of a new anxiety scale. 
Mov Disord. 2014 Jul;29(8):1035-43. 
72. Dissanayaka NN, O'Sullivan JD, Pachana NA, Marsh R, Silburn PA, White EX, et al. 
Disease-specific anxiety symptomatology in Parkinson's disease. Int Psychogeriatr. 2016 
Jul;28(7):1153-63. 
73. Martinez-Ramirez D, Giugni JC, Almeida L, Walz R, Ahmed B, Chai FA, et al. 
Association between antidepressants and falls in Parkinson's disease. Journal of neurology. 
2016 Jan;263(1):76-82. 
74. ffytche DH, Creese B, Politis M, Chaudhuri KR, Weintraub D, Ballard C, et al. The 
psychosis spectrum in Parkinson disease. Nat Rev Neurol. 2017 Feb;13(2):81-95. 
75. Nebe A, Ebersbach G. Selective diplopia in Parkinson's disease: a special subtype of 
visual hallucination? Mov Disord. 2007 Jun 15;22(8):1175-8. 
76. Urwyler P, Nef T, Killen A, Collerton D, Thomas A, Burn D, et al. Visual complaints and 
visual hallucinations in Parkinson's disease. Parkinsonism & related disorders. 2014 
Mar;20(3):318-22. 
77. Papapetropoulos S, Katzen H, Schrag A, Singer C, Scanlon BK, Nation D, et al. A 
questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease. BMC Neurol. 
2008 Jun 20;8:21. 
78. Fenelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci. 
2010 Feb 15;289(1-2):12-7. 
79. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced 
Parkinson's disease. Neurology. 1993;43:2227-9. 
80. Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, et al. 
Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work 
group. Mov Disord. 2007 Jun 15;22(8):1061-8. 
81. Jaakkola E, Joutsa J, Makinen E, Johansson J, Kaasinen V. Ventral striatal 
dopaminergic defect is associated with hallucinations in Parkinson's disease. European 
journal of neurology : the official journal of the European Federation of Neurological 
Societies. 2017 Nov;24(11):1341-7. 
82. Ballanger B, Strafella AP, van Eimeren T, Zurowski M, Rusjan PM, Houle S, et al. 
Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol. 2010 
Apr;67(4):416-21. 
83. Collerton D, Perry E, McKeith I. Why people see things that are not there: a novel 
Perception and Attention Deficit model for recurrent complex visual hallucinations. Behav 
Brain Sci. 2005 Dec;28(6):737-57; discussion 57-94. 
 31 
84. Lenka A, Jhunjhunwala KR, Saini J, Pal PK. Structural and functional neuroimaging in 
patients with Parkinson's disease and visual hallucinations: A critical review. Parkinsonism & 
related disorders. 2015 Jul;21(7):683-91. 
85. Jacobson SA, Morshed T, Dugger BN, Beach TG, Hentz JG, Adler CH, et al. Plaques 
and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual 
hallucinations. Parkinsonism & related disorders. 2014 Sep;20(9):1009-14. 
86. Bishara D, Harwood D, Sauer J, Taylor DM. Anticholinergic effect on cognition (AEC) 
of drugs commonly used in older people. Int J Geriatr Psychiatry. 2017 Jun;32(6):650-6. 
87. Collerton D, Dudley R. A cognitive behavioural framework for the treatment of 
distressing visual hallucinations in older people. Behav Cogn Psychoth. 2004 Oct;32(4):443-
55. 
88. Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, et al. Effects of 
rivastigmine in patients with and without visual hallucinations in dementia associated with 
Parkinson's disease. Mov Disord. 2006 Nov;21(11):1899-907. 
89. Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. 
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-
controlled phase 3 trial. Lancet. 2014 Feb 8;383(9916):533-40. 
90. Parkinson Study G. Low-dose clozapine for the treatment of drug-induced psychosis 
in Parkinson's disease. N Engl J Med. 1999 Mar 11;340(10):757-63. 
91. Wolters EC, Hurwitz TA, Mak E, Teal P, Peppard FR, Remick R, et al. Clozapine in the 
treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology. 1990 
May;40(5):832-4. 
92. National Institute for Health and Care Excellence. Parkinson’s disease in adults.  2017  
[cited 1st May 2018]; Available from: 
https://www.nice.org.uk/guidance/ng71/chapter/Recommendations#pharmacological-
management-of-non-motor-symptoms 
93. Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, 
unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in 
Parkinson's disease. Mov Disord. 2005 Aug;20(8):958-63. 
94. Kurlan R, Cummings J, Raman R, Thal L, Alzheimer's Disease Cooperative Study G. 
Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. 
Neurology. 2007 Apr 24;68(17):1356-63. 
95. Shotbolt P, Samuel M, Fox C, David AS. A randomized controlled trial of quetiapine 
for psychosis in Parkinson's disease. Neuropsychiatric disease and treatment. 2009;5:327-
32. 
96. Ueda S, Koyama K, Okubo Y. Marked improvement of psychotic symptoms after 
electroconvulsive therapy in Parkinson disease. The journal of ECT. 2010 Jun;26(2):111-5. 
97. Usui C, Hatta K, Doi N, Kubo S, Kamigaichi R, Nakanishi A, et al. Improvements in 
both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral 
blood flow after electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry. 
2011 Aug 15;35(7):1704-8. 
98. van Laar T, Postma AG, Drent M. Continuous subcutaneous infusion of apomorphine 
can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations. 
Parkinsonism & related disorders. 2010 Jan;16(1):71-2. 
99. Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients 
with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 2012 
Aug;11(8):697-707. 
 32 
100. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and 
characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 
2003 Mar;60(3):387-92. 
101. Lin CH, Wu RM. Biomarkers of cognitive decline in Parkinson's disease. Parkinsonism 
Relat Disord. 2015 May;21(5):431-43. 
102. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical 
diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007 Sep 
15;22(12):1689-707; quiz 837. 
103. Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, et al. 
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder 
Society Task Force guidelines. Mov Disord. 2012 Mar;27(3):349-56. 
104. Pedersen KF, Larsen JP, Tysnes OB, Alves G. Prognosis of mild cognitive impairment 
in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol. 2013 
May;70(5):580-6. 
105. Sauerbier A, Jenner P, Todorova A, Chaudhuri KR. Non motor subtypes and 
Parkinson's disease. Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S41-6. 
106. Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, Collins C, et al. Lewy- 
and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? 
Brain. 2011 May;134(Pt 5):1493-505. 
107. Howlett DR, Whitfield D, Johnson M, Attems J, O'Brien JT, Aarsland D, et al. Regional 
Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias. 
Brain Pathol. 2015 Jul;25(4):401-8. 
108. Ballard C, Ziabreva I, Perry R, Larsen JP, O'Brien J, McKeith I, et al. Differences in 
neuropathologic characteristics across the Lewy body dementia spectrum. Neurology. 2006 
Dec 12;67(11):1931-4. 
109. Skorvanek M, Goldman JG, Jahanshahi M, Marras C, Rektorova I, Schmand B, et al. 
Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. 
Mov Disord. 2017 Nov 23. 
110. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. 
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive 
impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. 
111. Jurica P, Leitten C, Mattis S. Psychological Assessment Resources, 2001. Dementia 
Rating Scale-2 (DRS-2). Arch Clin Neuropsy- chol 2004;19:145-7. 
112. Pagonabarraga J, Kulisevsky J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B, 
Gironell A. Parkinson's disease-cognitive rating scale: a new cognitive scale specific for 
Parkinson's disease. Mov Disord. 2008 May 15;23(7):998-1005. 
113. Chen L, Yu C, Zhang N, Liu J, Liu W. Cognitive impairment in patients with Parkinson's 
disease: A 30-month follow-up study. Clin Neurol Neurosurg. 2016 Dec;151:65-9. 
114. Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, et 
al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology. 
2010 Nov 9;75(19):1717-25. 
115. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for 
grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-
98. 
116. Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke's Cognitive 
Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J 
Geriatr Psychiatry. 2006 Nov;21(11):1078-85. 
 33 
117. Hsieh S, Schubert S, Hoon C, Mioshi E, Hodges JR. Validation of the Addenbrooke's 
Cognitive Examination III in frontotemporal dementia and Alzheimer's disease. Dement 
Geriatr Cogn Disord. 2013;36(3-4):242-50. 
118. Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet. 2015 Oct 
24;386(10004):1683-97. 
119. Mueller C, Ballard C, Corbett A, Aarsland D. The prognosis of dementia with Lewy 
bodies. Lancet Neurol. 2017 May;16(5):390-8. 
120. Jurado-Coronel JC, Avila-Rodriguez M, Echeverria V, Hidalgo OA, Gonzalez J, Aliev G, 
et al. Implication of Green Tea as a Possible Therapeutic Approach for Parkinson Disease. 
CNS Neurol Disord Drug Targets. 2016;15(3):292-300. 
121. Postuma RB, Lang AE, Munhoz RP, Charland K, Pelletier A, Moscovich M, et al. 
Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology. 2012 
Aug 14;79(7):651-8. 
122. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine 
for dementia associated with Parkinson's disease. N Engl J Med. 2004 Dec 9;351(24):2509-
18. 
123. Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, et al. Donepezil 
in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Mov 
Disord. 2012 Sep 1;27(10):1230-8. 
124. Wang HF, Yu JT, Tang SW, Jiang T, Tan CC, Meng XF, et al. Efficacy and safety of 
cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, 
Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with 
meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015 
Feb;86(2):135-43. 
125. Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. Memantine 
in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-
blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009 Jul;8(7):613-8. 
126. Ehrt U, Broich K, Larsen JP, Ballard C, Aarsland D. Use of drugs with anticholinergic 
effect and impact on cognition in Parkinson's disease: a cohort study. J Neurol Neurosurg 
Psychiatry. 2010 Feb;81(2):160-5. 
127. Bishara D, Harwood D, Sauer J, Taylor DM. Anticholinergic effect on cognition (AEC) 
of drugs commonly used in older people. Int J Geriatr Psychiatry. 2016 Jun 09. 
128. Yarnall AJ, Lawson RA, Duncan GW, Breen DP, Khoo TK, Brooks D, et al. 
Anticholinergic Load: Is there a Cognitive Cost in Early Parkinson's Disease? J Parkinsons Dis. 
2015;5(4):743-7. 
129. Reynolds GO, Otto MW, Ellis TD, Cronin-Golomb A. The Therapeutic Potential of 
Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease. Mov Disord. 2016 
Jan;31(1):23-38. 
130. Leung IH, Walton CC, Hallock H, Lewis SJ, Valenzuela M, Lampit A. Cognitive training 
in Parkinson disease: A systematic review and meta-analysis. Neurology. 2015 Nov 
24;85(21):1843-51. 
131. Robert P, Onyike CU, Leentjens AF, Dujardin K, Aalten P, Starkstein S, et al. Proposed 
diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. 
Eur Psychiatry. 2009 Mar;24(2):98-104. 
132. Drijgers RL, Dujardin K, Reijnders JS, Defebvre L, Leentjens AF. Validation of 
diagnostic criteria for apathy in Parkinson's disease. Parkinsonism Relat Disord. 2010 
Dec;16(10):656-60. 
 34 
133. Bostrom F, Jonsson L, Minthon L, Londos E. Patients with dementia with lewy bodies 
have more impaired quality of life than patients with Alzheimer disease. Alzheimer Dis Assoc 
Disord. 2007 Apr-Jun;21(2):150-4. 
134. Brodaty H, Burns K. Nonpharmacological management of apathy in dementia: a 
systematic review. Am J Geriatr Psychiatry. 2012 Jul;20(7):549-64. 
135. Holtta EH, Laakkonen ML, Laurila JV, Strandberg TE, Tilvis RS, Pitkala KH. Apathy: 
prevalence, associated factors, and prognostic value among frail, older inpatients. J Am Med 
Dir Assoc. 2012 Jul;13(6):541-5. 
136. Volicer L, Frijters DH, van der Steen JT. Apathy and weight loss in nursing home 
residents: longitudinal study. J Am Med Dir Assoc. 2013 Jun;14(6):417-20. 
137. Ishii S, Weintraub N, Mervis JR. Apathy: a common psychiatric syndrome in the 
elderly. J Am Med Dir Assoc. 2009 Jul;10(6):381-93. 
138. Santangelo G, Trojano L, Barone P, Errico D, Grossi D, Vitale C. Apathy in Parkinson's 
disease: diagnosis, neuropsychological correlates, pathophysiology and treatment. Behav 
Neurol. 2013 Jan 01;27(4):501-13. 
139. Skorvanek M, Nagyova I, Rosenberger J, Krokavcova M, Ghorbani Saeedian R, 
Groothoff JW, et al. Clinical determinants of primary and secondary fatigue in patients with 
Parkinson's disease. Journal of neurology. 2013 Jun;260(6):1554-61. 
140. Skorvanek M, Gdovinova Z, Rosenberger J, Saeedian RG, Nagyova I, Groothoff JW, et 
al. The associations between fatigue, apathy, and depression in Parkinson's disease. Acta 
Neurol Scand. 2015 Feb;131(2):80-7. 
141. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. 
Reliability, validity, and clinical correlates of apathy in Parkinson's disease. The Journal of 
neuropsychiatry and clinical neurosciences. 1992 Spring;4(2):134-9. 
142. Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy 
Evaluation Scale. Psychiatry Res. 1991 Aug;38(2):143-62. 
143. Sockeel P, Dujardin K, Devos D, Deneve C, Destee A, Defebvre L. The Lille apathy 
rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in 
Parkinson's disease. J Neurol Neurosurg Psychiatry. 2006 May;77(5):579-84. 
144. Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, et al. 
Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. 
Mov Disord. 2008 Oct 30;23(14):2004-14. 
145. Hopman-Rock M, Staats PG, Tak EC, Droes RM. The effects of a psychomotor 
activation programme for use in groups of cognitively impaired people in homes for the 
elderly. Int J Geriatr Psychiatry. 1999 Aug;14(8):633-42. 
146. Telenius EW, Engedal K, Bergland A. Effect of a high-intensity exercise program on 
physical function and mental health in nursing home residents with dementia: an assessor 
blinded randomized controlled trial. PLoS One. 2015;10(5):e0126102. 
147. Politis AM, Vozzella S, Mayer LS, Onyike CU, Baker AS, Lyketsos CG. A randomized, 
controlled, clinical trial of activity therapy for apathy in patients with dementia residing in 
long-term care. Int J Geriatr Psychiatry. 2004 Nov;19(11):1087-94. 
148. Chapman SB, Weiner MF, Rackley A, Hynan LS, Zientz J. Effects of cognitive-
communication stimulation for Alzheimer's disease patients treated with donepezil. J 
Speech Lang Hear Res. 2004 Oct;47(5):1149-63. 
149. Lam LC, Lui VW, Luk DN, Chau R, So C, Poon V, et al. Effectiveness of an 
individualized functional training program on affective disturbances and functional skills in 
 35 
mild and moderate dementia--a randomized control trial. Int J Geriatr Psychiatry. 2010 
Feb;25(2):133-41. 
150. Verkaik R, van Weert JC, Francke AL. The effects of psychosocial methods on 
depressed, aggressive and apathetic behaviors of people with dementia: a systematic 
review. Int J Geriatr Psychiatry. 2005 Apr;20(4):301-14. 
151. Holmes C, Knights A, Dean C, Hodkinson S, Hopkins V. Keep music live: music and the 
alleviation of apathy in dementia subjects. Int Psychogeriatr. 2006 Dec;18(4):623-30. 
152. Berman K, Brodaty H, Withall A, Seeher K. Pharmacologic treatment of apathy in 
dementia. Am J Geriatr Psychiatry. 2012 Feb;20(2):104-22. 
153. den Brok MG, van Dalen JW, van Gool WA, Moll van Charante EP, de Bie RM, Richard 
E. Apathy in Parkinson's disease: A systematic review and meta-analysis. Mov Disord. 2015 
May;30(6):759-69. 
154. Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Dubois B. Motivation, reward, 
and Parkinson's disease: influence of dopatherapy. Neuropsychologia. 2002;40(13):2257-67. 
155. Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ. The effect of 
pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of 
placebo-controlled studies. Clin Ther. 2009 Jan;31(1):89-98. 
156. Czernecki V, Schupbach M, Yaici S, Levy R, Bardinet E, Yelnik J, et al. Apathy following 
subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov 
Disord. 2008 May 15;23(7):964-9. 
157. Kaji Y, Hirata K. Apathy and anhedonia in Parkinson's disease. ISRN Neurol. 
2011;2011:219427. 
158. Chatterjee A, Fahn S. Methylphenidate treats apathy in Parkinson's disease. The 
Journal of neuropsychiatry and clinical neurosciences. 2002 Fall;14(4):461-2. 
159. Rosenberg PB, Lanctot KL, Drye LT, Herrmann N, Scherer RW, Bachman DL, et al. 
Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, 
placebo-controlled trial. J Clin Psychiatry. 2013 Aug;74(8):810-6. 
160. Weintraub D, Mavandadi S, Mamikonyan E, Siderowf AD, Duda JE, Hurtig HI, et al. 
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. 
Neurology. 2010 Aug 03;75(5):448-55. 
161. Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, et al. Pharmacological 
Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. Am J 
Psychiatry. 2015 Aug 1;172(8):731-42. 
162. Devos D, Moreau C, Maltete D, Lefaucheur R, Kreisler A, Eusebio A, et al. 
Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's 
disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg 
Psychiatry. 2014 Jun;85(6):668-74. 
163. Moretti R, Caruso P, Dal Ben M. Rivastigmine as a Symptomatic Treatment for 
Apathy in Parkinson's Dementia Complex: New Aspects for This Riddle. Parkinsons Dis. 
2017;2017:6219851. 
164. Levin OS. Coaxil (tianeptine) in the treatment of depression in Parkinson's disease. 
Neurosci Behav Physiol. 2007 May;37(4):419-24. 
165. Zahodne LB, Bernal-Pacheco O, Bowers D, Ward H, Oyama G, Limotai N, et al. Are 
selective serotonin reuptake inhibitors associated with greater apathy in Parkinson's 
disease? The Journal of neuropsychiatry and clinical neurosciences. 2012 
Summer;24(3):326-30. 
 36 
166. Rajkumar AP, Ballard C, Fossey J, Corbett A, Woods B, Orrell M, et al. Apathy and Its 
Response to Antipsychotic Review and Nonpharmacological Interventions in People With 
Dementia Living in Nursing Homes: WHELD, a Factorial Cluster Randomized Controlled Trial. 
J Am Med Dir Assoc. 2016 Aug 01;17(8):741-7. 
167. Starkstein SE. Apathy in Parkinson's disease: diagnostic and etiological dilemmas. 
Mov Disord. 2012 Feb;27(2):174-8. 
168. Kirsch-Darrow L, Zahodne LB, Marsiske M, Okun MS, Foote KD, Bowers D. The 
trajectory of apathy after deep brain stimulation: from pre-surgery to 6 months post-
surgery in Parkinson's disease. Parkinsonism Relat Disord. 2011 Mar;17(3):182-8. 
169. Thobois S, Ardouin C, Lhommee E, Klinger H, Lagrange C, Xie J, et al. Non-motor 
dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and 
underlying mesolimbic denervation. Brain. 2010 Apr;133(Pt 4):1111-27. 
170. Oguro H, Nakagawa T, Mitaki S, Ishihara M, Onoda K, Yamaguchi S. Randomized Trial 
of Repetitive Transcranial Magnetic Stimulation for Apathy and Depression in Parkinson's 
Disease. J Neurol Neurophysiol. 2014;05:6. 
171. Titova N, Qamar MA, Chaudhuri KR. The Nonmotor Features of Parkinson's Disease. 
Int Rev Neurobiol. 2017;132:33-54. 
 
Establish clinical diagnosis of depression
• Rule out other organic causes
• Assess if depression related to ‘off’ periods or non-motor 
fluctuations. These require adjustment of dopaminergic 
medication (consider Pramipexole).
• Establish severity of depression (e.g. MADRS, BDI, HAM-D) 
Antidepressant
Switch to a different 
antidepressant (consider switching 
SSRI to venlafaxine/TCA)  
Mild depression
• Self-help CBT
• Individual or group CBT
• Physical activity (e.g. 
exercise groups)
• Sleep hygiene
• Support group
• Carer involvement
Moderate or severe  depression
Individual or group CBT and/or
1st line: SSRI
• Citalopram
• Sertraline (especially 
if relevant cardiac 
disease)
• Paroxetine
If quick resolution of 
symptoms required 
and no relevant 
cardiac disease: TCA
• Nortriptyline 
• Desipramine
(Imipramine)
Switch to a different 
antidepressant
(preferably use SSRI)
• If no effect: consider adding pramipexole or other antidepressants
• If life-threatening/psychotic depression or patient’s preference: consider ECT
Poorly toleratedNo effect after 3-4 weeks 
at therapeutic dose
Screen for presence of depression:
• One positive answer on Two-question screening test
• Score of > 5 on GDS-15
No effect after 3-4 weeks 
at therapeutic dose
• Psychological intervention  
•Cholinesterase inhibitor
• Pimavanserin
• Clozapine
• (Quetiapine) 
• Dopamine therapy review 
• Review anti-muscarinic load 
• Infection / delirium screen
• Optimise vision  
Further investigations 
if hallucinations not 
typical of PD  
• Reassurance
• Education
• Self- help strategies
Minor symptoms 
Hallucinations 
with insight  
Hallucinations 
without insight
Delusions
Misidentification
If symptoms distressing 
• (Apomorphine)
• (ECT)
